- Report
- December 2025
- 150 Pages
Global
From €5370EUR$5,950USD£4,665GBP
- Report
- January 2026
- 192 Pages
Global
From €3199EUR$3,545USD£2,780GBP
€3555EUR$3,939USD£3,088GBP
- Report
- March 2026
- 483 Pages
Global
From €5279EUR$5,850USD£4,587GBP
- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,520GBP
- Report
- October 2025
- 160 Pages
Global
From €3030EUR$3,358USD£2,632GBP
€3565EUR$3,950USD£3,097GBP
- Report
- May 2025
- 73 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2256EUR$2,500USD£1,960GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1805EUR$2,000USD£1,568GBP
- Report
- June 2025
- 150 Pages
India
From €5370EUR$5,950USD£4,665GBP
- Report
- October 2025
- 89 Pages
Qatar
From €4377EUR$4,850USD£3,803GBP
- Report
- July 2025
- 90 Pages
Japan
From €5009EUR$5,550USD£4,352GBP
The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more
